60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2023-04, Vol.18 (4), p.S39-S40
Main Authors: Neal, J., Pavlakis, N., Kim, S-W., Goto, Y., Lim, S.M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D.C.C., Bearz, A., Quantin, X., Palmero, R., Antic, V., Chun, E., Edubilli, T. Rao, Lin, Y-C., Huseni, M., Scheffold, C., Vervaet, P., Newsom-Davis, T.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1556-0864
DOI:10.1016/S1556-0864(23)00260-5